PTLF (Petlife Pharmaceuticals) EBIT: $-3.21 Mil (TTM As of Feb. 2018)


What is Petlife Pharmaceuticals EBIT?

Petlife Pharmaceuticals PTLF EBIT is $-3.21 Mil as of Feb. 2018.

Petlife Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2018 was $-0.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2018 was $-3.21 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Petlife Pharmaceuticals's annualized ROC % for the quarter that ended in Feb. 2018 was -56.77%. Petlife Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2018 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Petlife Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2018 was -16,040.00%.

Petlife Pharmaceuticals  (OTCPK:PTLF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Petlife Pharmaceuticals's annualized ROC % for the quarter that ended in Feb. 2018 is calculated as:

ROC % (Q: Feb. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2017 ) + Invested Capital (Q: Feb. 2018 ))/ count )
=-0.732 * ( 1 - 0% )/( (1.192 + 1.387)/ 2 )
=-0.732/1.2895
=-56.77 %

where

Invested Capital(Q: Nov. 2017 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.058 - 0.638 - ( 0.054 - max(0, 1.83 - 0.058+0.054))
=1.192

Invested Capital(Q: Feb. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.008 - 0.594 - ( 0.008 - max(0, 1.981 - 0.008+0.008))
=1.387

Note: The Operating Income data used here is four times the quarterly (Feb. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

Petlife Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2018 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2017  Q: Feb. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.532/( ( (0 + max(-1.082, 0)) + (0 + max(-1.179, 0)) )/ 2 )
=-1.532/( ( 0 + 0 )/ 2 )
=-1.532/0
= %

where Working Capital is:

Working Capital(Q: Nov. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.004) - (0.638 + 0 + 0.448)
=-1.082

Working Capital(Q: Feb. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.594 + 0 + 0.585)
=-1.179

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Petlife Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2018 )
=-3.208/0.020
=-16,040.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals EBIT Related Terms

Petlife Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals EBIT Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.51 -1.51 -1.93 -3.69 -22.87

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.26 -0.81 -1.63 -0.38 -0.38

PTLF vs PCYN, YBAO, BKIT: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petlife Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petlife Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petlife Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Petlife Pharmaceuticals's EV-to-EBIT falls into.


Petlife Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-3.21 Mil mean?
Petlife Pharmaceuticals (PTLF) has a EBIT of $-3.21 Mil as of Feb. 2018. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Petlife Pharmaceuticals.
Is Petlife Pharmaceuticals' EBIT too high?
Petlife Pharmaceuticals' current EBIT is $-3.21 Mil.
How does Petlife Pharmaceuticals' EBIT compare to PCYN and YBAO?
Petlife Pharmaceuticals' EBIT of $-3.21 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Petlife Pharmaceuticals. Petlife Pharmaceuticals's current EBIT is $-3.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current EBIT of $-3.21 Mil. The current EBIT is $-3.21 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current EBIT is $-3.21 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.